Investment Rating - The report assigns an "Outperform" rating to the company, with a target price reduced to 54.86 RMB based on a target PE of 20X for 2025 [4][7]. Core Insights - The company achieved a revenue of 4.54 billion RMB in 2024, reflecting a growth of 15.41%, and a net profit attributable to shareholders of 1.83 billion RMB, which is a 10.57% increase [4][7]. - The overseas revenue share increased to 37% in 2024, with robust growth in international markets, particularly a 27.67% increase in overseas sales [9][8]. - Domestic growth slowed due to centralized procurement of reagents, while the company plans to continue focusing on enhancing its global competitiveness [8][9]. Financial Summary - Revenue projections for the company are as follows: 3,930 million RMB in 2023, 4,535 million RMB in 2024, 5,227 million RMB in 2025, and 6,028 million RMB in 2026, with respective growth rates of 29.0%, 15.4%, 15.3%, and 15.3% [3]. - Net profit attributable to shareholders is forecasted to be 1,654 million RMB in 2023, 1,828 million RMB in 2024, 2,155 million RMB in 2025, and 2,479 million RMB in 2026, with growth rates of 24.5%, 10.5%, 17.9%, and 15.0% respectively [3]. - The earnings per share (EPS) are projected to be 2.10 RMB in 2024, 2.33 RMB in 2025, and 3.16 RMB in 2026 [3][4].